| 2019-02-11 18:37:41|
GILD 18:37 02/11 02/11/19
Gilead downgraded to Market Perform from Outperform at Wells Fargo
Wells Fargo Securities analyst Jim Birchenough downgraded Gilead Sciences to Market Perform from Outperform and lowered his price target for the shares to $68 from $89. The analyst sees a lack of growth catalysts for the company following tonight's Phase 3 trial failure in nonalcoholic steatohepatitis. Gilead in after-hours trading is down 4%, or $2.62, to $65.00.
See Street Research during your Free Trial